Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023151 | 0.93 | HSD17B10 (0.49) | HSD17B10ATAD2CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL423546 | 0.85 | CYP11B2 (0.44) | CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1 | |
| SCHEMBL1744184 | 0.85 | CYP11B2 (0.40) | HSD17B10ATAD2CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL30896361 | 0.85 | CYP11B2 (0.40) | HSD17B10ATAD2CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL3344498 | 0.80 | ATAD2 (0.44) | ATAD2CYP11B2CYP11B1CYP19A1CYP1A2 | |
| SCHEMBL5986162 | 0.79 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1 | |
| SCHEMBL3344187 | 0.79 | ATAD2 (0.43) | HSD17B10ATAD2BRD4 | |
| SCHEMBL30896346 | 0.76 | BRD4 (0.63) | CYP11B2CYP11B1CYP19A1BRD4CREBBP | |
| SCHEMBL29642924 | 0.76 | CYP3A4 (0.41) | HSD17B10ATAD2CYP1A2CYP3A4 | |
| SCHEMBL12057333 | 0.75 | CYP11B1 (0.52) | CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| CN-102264723-B | Dihydropyridone amides as p2x7 modulators | HOFFMANN LA ROCHE | 2014-12-10 | — | — | CN | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| CN-102264723-A | Dihydropyridone amides as p2x7 modulators | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2385939-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8041551-B1 | Algorithm and architecture for multi-argument associative operations that minimizes the number of components using a latency of the components | THE MATHWORKS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | HSD17B10 4507/4885ATAD2 2666/4885CYP11B2 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.